These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 8858471)

  • 1. Efficacy and tolerance of amphotericin B in a lipid emulsion in the treatment of visceral leishmaniasis in AIDS patients.
    Petit N; Parola P; Dhiver C; Gastaut JA
    J Antimicrob Chemother; 1996 Jul; 38(1):154-7. PubMed ID: 8858471
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of visceral Leismaniasis in HIV patients with a new regimen of liposomal amphotericin].
    Canora Lebrato J; Troncoso García E; Escobar T; Hernández Quero J
    Med Clin (Barc); 2001 Mar; 116(10):395. PubMed ID: 11333677
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus.
    Torre-Cisneros J; Villanueva JL; Kindelan JM; Jurado R; Sanchez-Guijo P
    Clin Infect Dis; 1993 Oct; 17(4):625-7. PubMed ID: 8268341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal Amphotericin B drug access for the treatment of leishmaniasis in Brazil.
    Mistro S; Rodrigues M; Rosa L; Camargo M; Badaró R
    Trop Med Int Health; 2016 Jun; 21(6):692-3. PubMed ID: 27037644
    [No Abstract]   [Full Text] [Related]  

  • 5. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis.
    Meyerhoff A
    Clin Infect Dis; 1999 Jan; 28(1):42-8; discussion 49-51. PubMed ID: 10028069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Nephrotic syndrome and acute pancreatitis related to glucantime administration].
    Valencia ME; Laguna F; González Lahoz J
    An Med Interna; 2000 Jan; 17(1):54. PubMed ID: 10730416
    [No Abstract]   [Full Text] [Related]  

  • 7. Changing pattern of visceral leishmaniasis, United Kingdom, 1985-2004.
    Malik AN; John L; Bruceson AD; Lockwood DN
    Emerg Infect Dis; 2006 Aug; 12(8):1257-9. PubMed ID: 16965709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of amphotericin B colloidal dispersion in the treatment of Mediterranean visceral leishmaniasis in immunocompetent adult patients.
    Gaeta GB; Maisto A; Di Caprio D; Scalone A; Pasquale G; Felaco FM; Galante D; Gradoni L
    Scand J Infect Dis; 2000; 32(6):675-7. PubMed ID: 11200380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-dose treatment shows effectiveness for Indian visceral leishmaniasis.
    Pirisi A
    Lancet; 2000 Sep; 356(9235):1086. PubMed ID: 11009153
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term remission of human immunodeficiency virus-associated visceral leishmaniasis after initiation of potent combination antiretroviral treatment: report of two cases.
    Mastroianni CM; d'Ettorre G; Forcina G; Corpolongo A; Dell'Isola S; Lichtner M; D'Agostino C; Trinchieri V; Santopadre P; Vullo V
    J Infect; 2000 Jan; 40(1):94-6. PubMed ID: 10762121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium antimony gluconate, amphotericin, and myocardial damage.
    Thakur CP
    Lancet; 1998 Jun; 351(9120):1928-9. PubMed ID: 9654264
    [No Abstract]   [Full Text] [Related]  

  • 12. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
    Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
    Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal amphotericin B for leishmaniasis treatment of AIDS patients unresponsive to antimonium compounds.
    Lazanas MC; Tsekes GA; Papandreou S; Harhalakis N; Scandali A; Nikiforakis E; Saroglou G
    AIDS; 1993 Jul; 7(7):1018-9. PubMed ID: 8357549
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment of leishmaniasis in HIV-positive patients.
    Laguna F
    Ann Trop Med Parasitol; 2003 Oct; 97 Suppl 1():135-42. PubMed ID: 14678640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visceral leishmaniasis (Kala-azar) in two patients with HIV-1 infection: atypical features and response to therapy.
    Hamour AA; Skelly R; Jowitt SN; Wilson GE; Curry A; Wilkins EG; Mandal BK
    J Infect; 1998 Mar; 36(2):217-20. PubMed ID: 9570658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of liposomal amphotericin B for visceral leishmaniasis under routine program conditions in Bihar, India.
    Sinha PK; Roddy P; Palma PP; Kociejowski A; Lima MA; Rabi Das VN; Gupta J; Kumar N; Mitra G; Saint-Sauveur JF; Seena S; Balasegaram M; Parreño F; Pandey K
    Am J Trop Med Hyg; 2010 Aug; 83(2):357-64. PubMed ID: 20682882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of visceral leishmaniasis.
    Ozsoylu S
    Turk J Pediatr; 2003; 45(3):280. PubMed ID: 14696814
    [No Abstract]   [Full Text] [Related]  

  • 19. [Visceral leishmaniasis in patient with HIV infection].
    Olea P; Pinilla J
    Rev Chilena Infectol; 2013 Apr; 30(2):216-20. PubMed ID: 23677161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of visceral leishmaniasis with liposomal amphotericin B in three immunocompromised patients].
    Rodríguez-Wilhelmi P; Panizo C; Ruza E; Rocha E
    Med Clin (Barc); 2001 Jan; 116(1):37-8. PubMed ID: 11181264
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.